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Abstract 
Introduction: Biomarkers such as α-defensin demonstrated to be a potentially useful option in 
periprosthetic joint infection (PJI) diagnosis. Recently, a new point-of-care test for α-defensin level 
detection in synovial fluid has been commercialized in Europe. The aim of this study is to compare 
the α-defensin test (SynovasureTM) diagnostic ability with the main available clinical tests for 
periprosthetic joint infection diagnosis in a practical clinical setting of a Bone Infection Unit. 
Methods: Between 2015 and 2017, 146 patients with suspected chronic PJI were screened with 
SynovasureTM. Seventy-three of these met the Musculoskeletal Infection Society (MSIS) criteria and 
were included in the analysis. According to MSIS criteria, 40 patients (54.7%) were classified as 
infected and 33 (45.3%) as not infected. The results obtained with SynovasureTM were recorded and 
compared with standard diagnostic methods for PJI diagnosis. 
Results: SynovasureTM showed a sensitivity of 85.0 % (95% CI 70.2 to 94.3) and a specificity of 96.9 
% (95% CI 83.8 to 99.9) for PJI detection. The positive likelihood ratio of SynovasureTM was 27.2 
(95% CI 3.9 to 188.1) and the negative likelihood ratio was 0.2 (95% CI 0.1 to 0.3). The diagnostic 
odds ratio was 181.3 (95% CI 20.7 to 1590.4). SynovasureTM demonstrated a statistical significant 
difference when compared to Erythrocyte Sedimentation Rate (ESR) and C-reactive Protein (CRP) 
specificity (at least one positive test) and preoperative culture sensitivity (1 positive culture). 
Conclusion: Our findings show that SynovasureTM sensitivity is lower than quantitative α-D test, 
but when compared to the main available tests shows a good specificity and the highest DOR. On 
the SF it is the easier test to do, due to the fact that it needs a minimal amount of SF and it is not 
limited by blood contamination or antibiotic use. Whereas there is no single standalone test, 
SynovasureTM should be considered a reliable additional test for periprosthetic joint infection 
diagnosis in everyday clinical practice. 
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Introduction 
Periprosthetic joint infection (PJI) is considered 
to be one of the most challenging complications in the 
orthopaedic field. PJI diagnosis and management 
remain a source of concern and a major socioeconomic 
burden worldwide [1,2]. It accounts for 15.6% of 
surgical revisions in total hip arthroplasty (THA) and 
is considered to be the dominant reason for failure 








arthroplasty (TKA) [3,4]. Numerous efforts have been 
made to improve the diagnosis of PJI. In 2011, the 
Musculoskeletal Infection Society (MSIS) provided a 
consensus statement in order to accomplish a shared 
definition of PJI [5]. This algorithm was modified in 
2013 [6]. Currently, the diagnosis of PJI relies on 
clinical parameters, serum biomarker (Erythrocyte 
Sedimentation Rate (ESR) and C-reactive Protein 
(CRP)), synovial fluid white blood cell (WBC) count 
and polymorphonuclear cell percentage, synovial 
fluid Leukocyte Esterase (LE) test, periprosthetic 
tissue culture and histological analyses, but none of 
them have proved to be a reliable test individually. 
In the last few years, a lot of attention has been 
focused on biomarkers in synovial fluid (SF). In 2014, 
a prospective study including 95 patients with painful 
hip or knee arthroplasties in which the authors 
evaluated 16 biomarkers involved in the immune 
reaction after a PJI. Five of them (α-defensin 1.3, 
neutrophil elastase 2, bactericidal/permeability – 
increasing protein, neutrophil gelatinase-associated 
lipocalin and lactoferrin) showed a 100% sensitivity 
and specificity in diagnosing PJI [7]. 
Alpha defensin (α-D) is a natural peptide of the 
innate immunity released mainly from 
polymorphonuclear cells in response to pathogens 
such as Gram-positive and Gram-negative bacteria, 
fungi and enveloped viruses. The antimicrobial 
properties of this peptide are due to the ability to 
induce depolarization of the cell membrane by means 
of a “channel-like” pore formation [8,9]. Several 
published reports claimed α-D to be the optimal 
biomarker for PJI showing high diagnostic accuracy 
and promising results when compared to other 
available tests [10-13]. This data was obtained through 
quantitative testing with enzyme-linked 
immunosorbent assay (ELISA) after centrifugation of 
the SF. Recently a new point-of-care test for PJI 
identification (Synovasure™, Zimmer Inc., Warsaw; 
IN) was commercialized in Europe. Synovasure™ 
was not cleared or approved by the U.S. Food and 
Drug Administration but it received the CE 
(European Conformity) marking in Europe. It 
provides a simple “yes or no” answer after 10 
minutes. Despite its widespread use to date only a 
little data about Synovasure™ accuracy and reliability 
has been published. Moreover, some recent reports 
claimed differences in sensitivity and specificity 
between qualitative and quantitative analysis of α-D 
[14,15]. 
We conducted a single-centre retrospective 
study based on a prospectively collected dataset to (1) 
assess the sensitivity, specificity and diagnostic ability 
of the Synovasure™ and (2) to compare the obtained 
results with those achieved with other available 
clinical tests for PJI diagnosis in a practical clinical 
setting of a regional reference Bone Infection Unit. 
Materials and Methods 
From November 2015 to April 2017, a total of 146 
patients were enrolled in a PJI study using the 
Synovasure™ test. Seventy-three patients did not 
match the MSIS inclusion criteria, leaving 73 patients 
for final statistical analysis. 
All patients gave written and informed consent 
to all the diagnostic and surgical procedures. Local 
Institutional Review Board approval was obtained 
before the retrospective evaluation. 
Inclusion criteria for this investigation were (1) 
patients with painful arthroplasty under evaluation 
for possible infection or arthroplasty revision (2) 
enough clinical and/or laboratory data for patient 
classification according to MSIS criteria (3) sufficient 
SF for α-D test. 
Antibiotic therapy at the moment of SF 
aspiration, SF blood contamination and metallosis 
were not considered exclusion criteria. 
Data about age, sex, relevant comorbidities, 
involved joint, reason for revision, SF blood 
contamination, antibiotic therapy at the time of SF 
aspiration and type of surgical treatment were 
recorded for each patient (Table 1).  
According to our diagnostic flow chart, all 
subjects were screened for serum ESR/CRP and SF 
aspiration was performed. Serum ESR and CRP were 
evaluated preoperatively. According to the best 
available evidence [16], a cut-off level of 30 mm/hr for 
ESR and 10 mg/L for CRP were chosen for positivity 
assessment. The test was considered positive if both 
serum analyses were positive. SF aspiration was 
always performed by a highly trained infectious 
disease consultant (more than 20 years’ experience in 
Musculoskeletal infections). A well-trained nurse 
(more than 10 years of duty in a bone infection unit) 
assisted all the procedures. SF aspiration was carried 
out in a dedicated room under sterile conditions (3 
times preparation of the skin with alcohol solution 
and draping) using a 21 Gauge needle. A freehand 
technique was employed for knee aspirations whereas 
hip aspirations were performed under fluoroscopy 
guidance. Immediately after the procedure, SF was 
partitioned for each laboratory investigation 
according to the collected volume. A separate sterile 
tube was obtained for microbiological culture. 
Synovasure™ was performed in the included 
patients prior to any SF manipulation according to the 
manufacturer’s instructions. The test was performed 
and read by an experienced operator (more than 20 
years-experience in Musculoskeletal infections and 
more than 1000 joint aspirations performed). The test 




kit comprised: a single use chromatographic device, a 
premeasured vial of dilution buffer, a disposable 
Microsafe tube, and a sample cup. The SF is placed in 
the sample cup. Dilution is obtained by collecting SF 
with the disposable Microsafe® tube and adding the 
sample to the premeasured dilution buffer. After 
gentle hand mixing, 3 drops of the obtained mix is 
added to the cassette. During its migration through 
the device the sample mixes with the gold conjugate 
labelled anti-defensin antibodies. The test was read 
after 10 minutes incubation. The presence of the 
control line (marked as C on the testing cassette) in all 
performed tests, confirmed the test validity. The test 
was considered positive if a second line (marked as 
a-D on the testing cassette) appeared. 
LE test was obtained in 67 patients. LE test was 
accomplished using the Multistix 10 SG (Siemens 
Healthcare Diagnostics Inc., Tarrytown, New York) 
reagent strip. The test is a simple colorimetric method 
and provides a semiquantitative result related to the 
concentration of leukocyte cells in the SF sample. The 
method is interpreted as negative (white), trace 
(off-white), + (slightly purple), ++ (light purple) or 
+++ (dark purple). SF was previously centrifuged at 
6000 g for 2 min if blood contamination was detected. 
A trained operator evaluated and registered the test 
strip data. We considered ++ and +++ results as 
positive tests. [17] 
WBC count and characterization were 
performed using an advanced automated 
hematological analyzer the Sysmex XN-9000 (Sysmex, 
Inc. Kobe, Japan) equipped with a specifically 
designed unit for body fluids analysis (XN-BF), using 
fluorescent flow cytometry with hydrodynamic 
focusing. Since the increased viscosity may impair 
sample aspiration or prevent appropriate mixing a 
pre-treatment of SF samples with the enzyme 
hyaluronidase (HY) was made.  
SF culture was obtained in all patients. 
Immediately after joint aspiration, a separate aliquot 
of SF was inoculated in aerobic (BacT / ALERT FA 
PLUS) and anaerobic (BacT / ALERT FN PLUS) 
bottles and taken to the laboratory by the nurse for 
microbiological testing. The bottles were incubated in 
the BacT / ALERT 3D instrument (software version 
B.40 Rel. 4). Gram staining was performed directly 
from the positive liquid, which was also inoculated in 
common solid media for subculture. Cultures were 
incubated for at least 14 days. The retrieved 
microorganisms along with negative results were 
recorded.  
Sixty-seven out of the 73 enrolled patients 
underwent surgery. All revisions were performed by 
the same experienced surgeon. Three to 6 
periprosthetic bioptic samples were sent to 
microbiological analysis by default.  
 
Table 1. Main demographic and surgical data.  
 
PJI: Periprosthetic Joint Infection. SF: Synovial Fluid 
 




According to intraoperative findings, frozen 
section for definitive histology evaluation was 
performed. An experienced pathologist specialized in 
musculoskeletal disorders processed all the 
specimens and interpreted the obtained results. 
Statistical analysis 
Continuous variables were reported as mean ± 
standard deviation and compared using the 
independent Student t-test or Mann-Whitney U test. 
Categorical variables were expressed as the number of 
cases or percentage. The sensitivity, specificity, 
positive likelihood ratio (LR+), negative likelihood 
ratio (LR-), Diagnostic Odds ratio (DOR) and relative 
Confidence Intervals (CI) were calculated for α-D, 
serum ESR/CRP, LE test, SF leukocyte count, 
preoperative culture, frozen section and definitive 
histology using MSIS criteria as the reference 
standard. SF polymorphonuclear cell percentage was 
not included in the analysis because of the low 
number of screened patients. We did not calculate the 
positive and negative predictive values and accuracy 
of the tests because the prevalence of PJI in our cohort 
of patients did not reflect the prevalence of PJI in the 
standard population. Sensitivity and specificity of α-D 
test were compared with other tests using the 
McNemar’s Chi square test. For all the analysed data, 
a p-value of <0.05 was considered statistically 
significant. 
Results 
Of the 73 included patients, 40 were considered 
septic according to modified MSIS criteria. The septic 
cohort of patients was composed of 23 males and 17 
females with an average age of 68.0 ± 12.4 years. All 
PJI were classified as chronic infections according to 
Zimmerli classification [18]. According to joint site 
distribution, there were 19 THA, 19 TKA and 2 
reverse shoulder arthroplasties (RSA). Thirty-seven 
patients underwent a two-stage revision after PJI 
diagnosis, 2 sustained a one-stage revision. One 
patient was treated with a Girdlestone resection 
arthroplasty.  
In this group, Synovasure™ tests were positive 
in 34 cases and negative in 6. All the negative patients 
had negative preoperative cultures, but at least 3 
positive intraoperative cultures for the same 
microorganism. These discordant cases are described 
below.  
The first patient suffered from Rheumatoid 
Arthritis (RA) and was under immunosuppressant 
therapy at the moment of evaluation. A THA infection 
diagnosis with the evidence of a communicating sinus 
was performed. An LE test was not performed 
because of blood contamination in the sample, even 
after centrifugation. Intraoperative frozen section was 
positive as well as definitive histology. 
Methicillin-Resistant Staphylococcus aureus (MRSA) 
was isolated from 4 out of 6 intraoperative cultures. A 
one-stage procedure was carried out. 
The second patient also had a history of RA, 
treated with steroid and immunosuppressant therapy. 
All preoperative analyses apart from CRP were 
negative. Intraoperatively, purulent synovial fluid 
was observed and a hip spacer was implanted. All the 
intraoperative cultures were positive (polimicrobic 
flora). The frozen section and definitive histology 
were also positive. 
The third patient was diagnosed with a THA 
infection according to intraoperative findings. 
Streptococcus anginosus was isolated in 3 culture 
samples. Definitive histology was positive even if the 
frozen section was not. LE test resulted negative. The 
only preoperative positive tests were ESR and CPR. 
According to intraoperative macroscopic analysis, the 
patients underwent a two-stage revision. 
The fourth patient had a history of RA, treated 
with steroid and immunosuppressant therapy. All 
preoperative analyses but CRP were negative. 
Intraoperatively, purulent synovial fluid was 
observed and a hip spacer was implanted. All the 
intraoperative cultures were positive (polimicrobic 
flora). The frozen section and definitive histology 
were also positive. 
The fifth patient was diagnosed with a THA 
infection after 11 surgical procedures. The only 
positive preoperative results were ESR and CRP. 
Intraoperatively, a Girdlestone procedure was 
performed because of the massive bone loss and the 
very poor general condition of the patient. 
Methicillin-Resistant Staphylococcus epidermidis 
(MRSE) was obtained from 3 intraoperative tissue 
cultures. 
The last false negative patient had a TKA 
infection with positive synovial WBC count while 
ESR/CRP and LE tests were negative. Staphylococcus 
capitis was isolated in 4 intraoperative samples. A 
two-stage procedure was carried out with positive 
outcome. 
The second group of patients (33 patients) 
considered aseptic according to the MSIS criteria was 
composed of 7 males and 26 females with an average 
age of 69.5 ± 7.5 years. Three THA’s and 33 TKA’s 
were included. All but 6 patients underwent total joint 
arthroplasty revision. One patient had a positive 
preoperative culture, which was considered as a 
contaminant.  
In this group, Synovasure™ showed one false 
positive result. This patient underwent evaluation for 
a painful hip arthroplasty. Preoperative blood tests 




were mildly positive and purulent SF was obtained 
even if the LE test and preoperative cultures were 
negative. Intraoperative findings revealed an intense 
inflammatory reaction of the periprosthetic tissues 
without evidence of metallosis but the intraoperative 
microbiological and histological analysis were 
negative. 
All patients underwent Synovasure™ testing as 
well as blood ESR/CRP tests and preoperative 
culture. An LE test was performed on 67 patients 
(91.8%). In 2 patients The LE test was not provided 
due to an SF shortage. In 4 patients, the massive blood 
contamination even after sample centrifugation 
prevented the test’s reliability.  
Due to insufficient SF retrieval, a synovial 
leukocyte count and neutrophil percentage were 
evaluated in 43 and 15 patients, respectively. 
Definitive histology and a frozen section were 
performed on 43 and 42 patients, respectively (Figure 
1). 
Overall, Synovasure™ showed a sensitivity of 
85.0 % (95% CI 70.2 to 94.3) and a specificity of 96.9 % 
(95% CI 83.8 to 99.9). Synovasure™ demonstrated a 
statistical significant difference when compared to 
ESR/CRP specificity and preoperative culture 
sensitivity (1 positive culture) (Table 2).  
The LR+ of α-D test was 27.2 (95% CI 3.9 to 188.1) 
and the LR- was 0.2 (95% CI 0.1 to 0.3). The DOR was 
181.3 (95% CI 20.7 to 1590.4) (Table 3). 
Nine patients were under antibiotic treatment at 
the moment of α-D testing. The sensitivity and 
specificity values of α-D test in this specific subset of 
patients were 85.71% (95% CI 42.1 to 99.6) and 100.0% 
(95% CI 15.8 to 100.0), respectively.  
SF blood contamination was reported in 24 
patients. Synovasure™ showed a sensitivity of 80.0% 
(95% CI 51.9 to 95.7) and a specificity of 100.0% (95% 
CI 71.5 to 100.0) in this group, while the same 
parameters for non-contaminated cohort of patients 
were 88.0% (95% CI 68.8 to 97.4) and 95.45% (95% CI 
77.2 to 99.9).  
No statistically significant difference was 
observed when comparing sensitivity and specificity 
values between the antibiotic-treated and the 
antibiotic-free population neither between 
contaminated blood and non-contaminated SF 
samples.  
Discussion 
The main findings of the presented study are 
that Synovasure™ showed a sensitivity of 85.0 %, a 
specificity of 96.9 %, a LR+ of 27.2 and a LR- of 0.2. 
The DOR was 181.3. When compared to other 
available tests for PJI diagnosis, Synovasure™ 
demonstrated a statistical significant difference when 
compared to ESR/CRP specificity and preoperative 
culture sensitivity (1 positive culture). Synovasure™ 
provided 6 false negatives and 1 false positive results. 
Among the false negatives, 3 patients were under 
immunosuppressive therapy. In all cases, PJI 
diagnosis was achieved with intraoperative analyses. 
In the false positive patient, an inflammatory reaction 
of periprosthetic tissues without evidence of 
metallosis was detected intraoperatively. 
 
 
Figure 1. The figure shows the number of patients screened for each test. The striped column represents the total number of patients included in the study. 
 




Table 2. Sensitivity and specificity data. The P values showed statistically significant differences only for ESR/CRP specificity and Culture 
sensitivity (bold type). 
 
ESR/CRP: Erythrocyte Sedimentation Rate/C-Reactive Protein 
CI: Confidence Interval 
 
Table 3. Diagnostic Odds Ratio (DOR), Positive Likelihood Ratio (LR+) and Negative Likelihood Ratio (LR-) of different tests. 
 
ESR/CRP: Erythrocyte Sedimentation Rate/C-Reactive Protein 
CI: Confidence Interval 
 
PJI is one of the most devastating complications 
of total joint arthroplasty with a relevant 
socioeconomic burden. More than 25% of revisions 
are attributed to infections, with a reported trend to 
increase [19-21]. Despite new achievements in this 
field, PJI diagnosis remains a serious challenge and no 
single standard reference test has been identified to 
date. 
Alpha defensins are a family of mammalian 
peptides, showing relevant microbicidal properties 
against many Gram-negative and Gram-positive 
bacteria, fungi, and enveloped viruses. They are 
produced, mainly by neutrophils, constitutively 
and/or in response to microbial products or 
proinflammatory cytokines. We performed a study in 
a Single specialized Centre for Bone Infections to 
evaluate the utility and possible added value of a 
POCT α-defensine qualitative test (Synovasure™) in 
our clinical setting. 
Published data shows promising results of α-D 
testing in PJI with a sensitivity ranging from 63% to 
100% [7,22-24] and a sensitivity of 63% on 
periprosthetic shoulder arthroplasty infection while 
in the hip and knee joints the sensitivity grows up to 
97% with a specificity of 95% to 100% [25].  




An independent study on sixty-one painful hip 
and knee arthroplasties or before second stage 
reimplantation showed a sensitivity and specificity of 
α-defensine testing of 100% and 95%, respectively. 
This test demonstrated better sensitivity and 
specificity when compared to culture, SF leukocyte 
count, ESR and CRP. No data about systemic 
inflammatory comorbidities or metallosis was 
presented [26]. 
Recently, Synovasure™, a new POCT test for 
qualitative assessment of α-D in the SF, has been 
developed and is now commercially available. To our 
knowledge, only 5 studies have been published about 
this new α-D test qualitative showing a general 
decrease in diagnostic accuracy when compared to 
immunoassay quantitative assay [27]. The results 
obtained from 40 hip and knee arthroplasty revisions 
(12 PJI according to MSIS criteria) lead to 2 main 
conclusions. Firstly, Synovasure™ provide high 
accuracy (85%) in PJI diagnosis, at least equivalent to 
intraoperative frozen section. The second conclusion 
confirms that, although Synovasure™ provides good 
results, they are not as good as previous data obtained 
with immunoassay laboratory test. The authors 
explained their false negative results with the 
contamination of samples with blood or cellular 
debris however our data, though in a limited number 
of cases, clearly shows that blood contamination does 
not influence the reliability of Synovasure™ test. In a 
single-centre study based on 49 patients, the authors 
achieved a sensitivity of 69% and a specificity of 94%. 
α-D qualitative test achieves the same accuracy of 
definitive histology and one positive culture [28]. One 
of the added values of a POCT device use for α-D 
testing in this specific clinical setting undoubtedly 
relies on its easiness and speed of use. Some false 
results could be partially explained by the fact that 15 
patients had an in-situ spacer at the moment of 
Synovasure™ test. A further matter of debate is 
whether α-D could be a reliable test even before a 
second stage revision.  
In another study aimed to evaluate the accuracy 
of quantitative α-D test in a cohort of 102 candidates 
for hip or knee revision surgery. Thirty-eight of them 
were second-stage revisions. Although optimal 
accuracy was achieved in first/single-stage revisions, 
the sensitivity, specificity, positive and negative 
likelihood ratios were 67%, 97%, 21 and 0.3 
respectively [29]. This data could be partially 
explained by the fact that MSIS criteria and α-D test 
have not been designed for second-stage revisions 
and by the low number of patients who may not be 
representative of a real setting. 
High performance of α-D lateral flow test in knee 
PJI diagnosis was demonstrated [30]. Although their 
data (sensitivity 87.5% and specificity 97.1%) are 
consistent with our results, the authors demonstrated 
the superiority of Synovasure™ in terms of sensitivity 
and negative predictive value when compared to 
other typical analyses (culture, synovial cell count, 
ESR and CRP). 
On the other hand, recently published data 
based on a multicentre study of a Cohort of 121 
patients was prospectively evaluated for painful hip 
and knee arthroplasties and screened for PJI with α-D 
test and MSIS criteria. In this setting, Synovasure™ 
showed a sensitivity, specificity, LR+ and LR- of 
97.1%, 96.5%, 28.2 and 0.03 respectively with an 
accuracy of 96.7%. Apart from SF leukocyte count, 
α-D overtakes all other MSIS diagnostic test [31]. The 
authors do not consider the LE test in the toolbox of 
possible tests for PJI and preferred to retain the 
purulence around the prosthesis as minor criterion 
making a real comparison with our series difficult. 
Similar data was recently reported utilizing the 
largest α-D cohort published up until now [32]. 191 
patients (195 joints) were screened for MSIS criteria 
and included in this prospective study. Synovasure™ 
test was performed on all patients and when possible, 
a quantitative ELISA test was carried out (173 
patients). Sensitivity, specificity, PPV and NPV of 
Synovasure™ test were 92.1%, 100 %, 100% and 
95.2%, respectively. The accuracy was 96.9%. 
Interestingly, the accuracy of the lateral flow analysis 
was 94.8% when compared to the laboratory 
immunoassay. 
According to our data, Synovasure™ test 
demonstrated statistical significant difference only 
when compared to 1 positive culture sensitivity and 
ESR/CRP specificity. Though these results, we were 
able to screen the whole cohort of patients only for 
α-D, blood test and culture analysis. LE was 
performed on 67 (91.8%) out of 73 patients due to 
blood contamination or lack of SF. This finding is in 
line with previous presented data [23]. They pointed 
out that the LE test was unreadable in eight of 46 
joints (17%) as a result of blood interference. Small 
volumes of retrieved SF limited leukocyte count and 
neutrophil percentage analysis (43 and 15 patients 
respectively). Moreover, intraoperative criteria such 
as frozen section and histology were available only in 
42 and 43 patients, respectively. This data clearly 
shows that a Synovasure™ test outperforms the 
majority of MSIS criteria in the number of potentially 
screenable patients. 
Some authors tried to improve the effectiveness 
of α-D in PJI diagnosis combining it with other serum 
or SF analysis [22] testing the combination of α-D and 
serum CRP dosage in 149 patients affected by painful 
arthroplasty, 37 of them were later diagnosed by PJI 




according to MSIS criteria. While the only α-D dosage 
demonstrated a specificity of 95.5% and a sensitivity 
of 97.3%, the combination of both tests resulted in a 
specificity of 100% and a sensitivity of 99.3%. Synovial 
CRP reversed all-false positive α-D data and lead to a 
correct diagnosis in 99% of patients. 
Combining our α-D results with LE data, 
Synovasure™ correctly reversed the only false 
positive tests obtained with LE. Out of the 8 false 
negatives LE tests, only 4 were diagnosed by α-D 
leading to a combined sensitivity of 88.2% (95% CI 
72.6 to 96.7) and specificity of 100 % (95% CI 89.4 to 
100). 
The Alpha-defensin test already shows its 
reliability regardless preceding antibiotic treatment 
[33]. Our data is consistent with this evidence and 
demonstrated that Synovasure™ is a reliable test even 
in presence of blood contamination of SF samples. The 
relatively high percentage (13.4%) of patients under 
antibiotic therapy started before referral to a 
specialized hospital, highlight the need of educational 
improvement of primary care providers who deal 
with patients with painful joint arthroplasty [34]. 
Undoubtedly, our study has some limitations. 
Point of care test seems to provide inferior results 
especially for sensitivity values when compared to 
quantitative immunoassay test, however we cannot 
directly compare our data with previously published 
evidence obtained with laboratory assays. Moreover, 
we did not succeed to screen all patients for each 
individual test. This limitation could be bias to the 
data analysis. The study lacks statistical power 
preventing us to draw firm conclusions. A final 
weakness is that we included patients under antibiotic 
therapy that could influence SF leukocyte count, 
neutrophil percentage, and culture and therefore 
compromise the diagnosis of PJI [35]. Nevertheless, 
the authors aimed to report a practical everyday life 
experience of a bone infection unit in which antibiotic 
therapy at the moment of SF aspiration and blood 
sample contamination are common situations. 
Conclusion 
Despite the limitations discussed above, our 
findings show that Synovasure™ sensitivity is lower 
than quantitative α-D test, but it is a reliable and 
easy-to-use option for PJI diagnosis when compared 
to current MSIS criteria. Synovasure™, compared to 
the main available tests, shows good specificity and 
the highest DOR. On the SF it is the easier test to do, 
due to the fact that it needs a minimal amount of SF 
and it is not limited by blood contamination or 
antibiotic use.  
Whereas there is no single stand alone test, we 
believe that Synovasure™ holds the potential to be 
included in the toolbox of tests for PJI diagnosis.  
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